|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM42 |
Gene summary for TMEM42 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM42 | Gene ID | 131616 |
| Gene name | transmembrane protein 42 | |
| Gene Alias | TMEM42 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q69YG0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 131616 | TMEM42 | LZE4T | Human | Esophagus | ESCC | 3.65e-03 | 9.48e-02 | 0.0811 |
| 131616 | TMEM42 | LZE7T | Human | Esophagus | ESCC | 8.00e-04 | 1.38e-01 | 0.0667 |
| 131616 | TMEM42 | LZE8T | Human | Esophagus | ESCC | 8.15e-03 | 7.57e-02 | 0.067 |
| 131616 | TMEM42 | LZE22T | Human | Esophagus | ESCC | 8.27e-03 | 2.23e-01 | 0.068 |
| 131616 | TMEM42 | LZE24T | Human | Esophagus | ESCC | 6.98e-08 | 2.08e-01 | 0.0596 |
| 131616 | TMEM42 | P1T-E | Human | Esophagus | ESCC | 2.49e-06 | 2.56e-01 | 0.0875 |
| 131616 | TMEM42 | P2T-E | Human | Esophagus | ESCC | 7.58e-17 | 1.78e-01 | 0.1177 |
| 131616 | TMEM42 | P4T-E | Human | Esophagus | ESCC | 3.52e-17 | 3.12e-01 | 0.1323 |
| 131616 | TMEM42 | P5T-E | Human | Esophagus | ESCC | 1.91e-11 | 6.95e-02 | 0.1327 |
| 131616 | TMEM42 | P8T-E | Human | Esophagus | ESCC | 4.58e-19 | 9.35e-02 | 0.0889 |
| 131616 | TMEM42 | P9T-E | Human | Esophagus | ESCC | 7.66e-10 | 2.08e-01 | 0.1131 |
| 131616 | TMEM42 | P10T-E | Human | Esophagus | ESCC | 7.77e-19 | 2.00e-01 | 0.116 |
| 131616 | TMEM42 | P11T-E | Human | Esophagus | ESCC | 1.20e-07 | 2.37e-01 | 0.1426 |
| 131616 | TMEM42 | P12T-E | Human | Esophagus | ESCC | 5.87e-20 | 2.84e-01 | 0.1122 |
| 131616 | TMEM42 | P15T-E | Human | Esophagus | ESCC | 4.91e-12 | 1.90e-01 | 0.1149 |
| 131616 | TMEM42 | P16T-E | Human | Esophagus | ESCC | 4.64e-22 | 2.19e-01 | 0.1153 |
| 131616 | TMEM42 | P17T-E | Human | Esophagus | ESCC | 2.10e-04 | 1.65e-01 | 0.1278 |
| 131616 | TMEM42 | P19T-E | Human | Esophagus | ESCC | 1.22e-08 | 4.34e-01 | 0.1662 |
| 131616 | TMEM42 | P20T-E | Human | Esophagus | ESCC | 2.36e-06 | 1.81e-01 | 0.1124 |
| 131616 | TMEM42 | P21T-E | Human | Esophagus | ESCC | 6.96e-29 | 3.74e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM42 | SNV | Missense_Mutation | novel | c.261N>A | p.Phe87Leu | p.F87L | Q69YG0 | protein_coding | tolerated(0.27) | possibly_damaging(0.775) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| TMEM42 | SNV | Missense_Mutation | novel | c.282N>A | p.Phe94Leu | p.F94L | Q69YG0 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM42 | SNV | Missense_Mutation | novel | c.313G>T | p.Val105Leu | p.V105L | Q69YG0 | protein_coding | tolerated(0.07) | benign(0.117) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM42 | SNV | Missense_Mutation | novel | c.282C>A | p.Phe94Leu | p.F94L | Q69YG0 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| TMEM42 | SNV | Missense_Mutation | novel | c.301N>A | p.Ala101Thr | p.A101T | Q69YG0 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM42 | SNV | Missense_Mutation | rs139324350 | c.409C>A | p.Leu137Ile | p.L137I | Q69YG0 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM42 | SNV | Missense_Mutation | c.245C>A | p.Ser82Tyr | p.S82Y | Q69YG0 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM42 | SNV | Missense_Mutation | c.245C>A | p.Ser82Tyr | p.S82Y | Q69YG0 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM42 | SNV | Missense_Mutation | novel | c.296C>T | p.Ala99Val | p.A99V | Q69YG0 | protein_coding | tolerated(0.09) | possibly_damaging(0.539) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM42 | SNV | Missense_Mutation | c.402C>A | p.Phe134Leu | p.F134L | Q69YG0 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |